.png){kind=small}
The Biomedical Polymer Durability Challenge
Implantable and drug delivery polymer systems operate in the most chemically aggressive biological environment imaginable. Physiological temperature (37°C), continuous fluid immersion, enzymatic activity, cyclic mechanical loading, and reactive oxygen species (ROS) act simultaneously on polymer biomaterials for months, years, or decades.
The consequences of polymer failure in biomedical applications are not a warranty claim. They are a device recall, an adverse event report, and in the worst cases, patient harm.
NuSil MED-4850 and Lubrizol NuSil Q7-4840 silicone implants experience oxidative degradation in inflammatory microenvironments and fatigue cracking under cyclic mechanical loading; physical durability testing at room temperature tells you almost nothing about what happens inside a patient at 37°C under ROS conditions
Evonik RESOMER R 202 H (PLGA) and PCL drug delivery scaffolds degrade through hydrolysis — and the degradation rate determines drug release kinetics; if the model is wrong, the therapeutic window is wrong
Lubrizol Pellethane 2363-80AE polyurethane tubing and catheters undergo hydrolytic stress cracking in physiological fluid environments at rates that vary dramatically with flow conditions and fluid chemistry
Rogers Corporation BISCO HT-800 silicone in class III devices must maintain mechanical properties under sustained load and physiological oxidative exposure for 10+ years
Regulatory pathways — FDA 510(k), PMA, CE Mark under EU MDR — require evidence of device performance over labeled service life. Standard ASTM F1980 accelerated aging applies Q10 factors to elevated-temperature oven tests. For polymers whose degradation is not purely Arrhenius-driven — hydrolysis-dominated PLGA, oxidative crosslinking in silicone, enzyme-catalyzed chain scission — Q10 extrapolation introduces systematic error in the direction regulators cannot see.
ElastoSure replaces the Q10 assumption with actual degradation physics.
How ElastoSure Addresses Electronic Packaging Polymer Aging
The dominant degradation pathway for Evonik RESOMER R 202 H (PLGA), Corbion PURASORB (PLA), and Perstorp Capa (PCL) drug delivery systems. K-Load models water absorption, ester bond cleavage, and molecular weight changes to predict mechanical integrity and drug release over time—the two key metrics evaluated in FDA drug/device combination submissions.
Models continuous immersion at 37°C with physiologically relevant ionic strength — the actual condition for implantable devices. Tracks swelling, elastic modulus drop, and toughness loss in PEG-based hydrogels, HA derivatives, and GelMA constructs over months to years of implant service.
Total hip and knee replacement UHMWPE (Orthoplastics 1900H, DSM Orthozilla GUR 1050) acetabular liners experience millions of gait cycles. K-Load predicts fatigue crack initiation and propagation under cyclic loading at physiological frequency and load magnitude, consistent with ISO 14242 hip simulator conditions.
Total hip and knee replacement UHMWPE (Orthoplastics 1900H, DSM Orthozilla GUR 1050) acetabular liners experience millions of gait cycles. K-Load predicts fatigue crack initiation and propagation under cyclic loading at physiological frequency and load magnitude, consistent with ISO 14242 hip simulator conditions.
Validation — Research-Grade Accuracy
K-Load achieves 95% improvement in 5-year degradation prediction accuracy over standard Arrhenius extrapolation across polymer systems. In electronic packaging applications, the hygrothermal aging module's predictions for epoxy-based encapsulant systems align with published IMAPS and IEEE ECTC accelerated aging data across multiple Tg ranges and filler loadings.
Biomedical Applications
PLGA / PLA Resorbable Device Life
Model Evonik RESOMER R 202 H molecular weight decline, Corbion PURASORB strength loss, and mass loss in PLGA screws, suture anchors, and drug delivery scaffolds. Predict resorption time and the mechanical support window for resorbable fixation devices.
Predict fatigue crack initiation in NuSil MED-4850 and Rogers BISCO HT-800 silicone elastomer shells under cyclic mechanical loading in oxidative biological environment. Support FDA PMA submissions with physics-based service life prediction data, replacing Q10 extrapolation with mechanistic degradation models.
Model degradation rate and drug release profile evolution for PEG-based, HA-derivative, and GelMA hydrogels under in vivo physiological pH, temperature, and ionic conditions. Predict when the therapeutic drug release window shifts beyond the intended range.
What You Get
Regulatory-aligned life prediction report — service life prediction structured to support ASTM F1980 equivalence arguments in FDA 510(k) or PMA submissions; comparison of K-Load physics-based prediction vs. Q10 Arrhenius extrapolation included
Degradation mechanism profile — hydrolysis vs. oxidation vs. fatigue contribution ranked by mechanism over time
Drug release profile prediction — for degradable drug delivery matrices: how drug release rate shifts as a function of PLGA/PLA degradation state
ASTM F1980-compatible accelerated test protocol — K-Suite designs the minimum 35-day accelerated test that generates calibration data for K-Load, then K-Load does the rest
Clinical follow-up alignment — if you have in vivo retrieval or clinical follow-up measurements, K-Suite calibrates to this data and extends predictions to the full device lifetime